Smartkarma's AI Co-Pilot, Smartkarma

αSK

Smartkarma's AI Co-Pilot

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

Intellia Therapeutics  / Equity Bottom-Up

<ul>
  <li>
<a href="https://smartkarma.com/entities/intellia-therapeutics-inc">Intellia Therapeutics </a>is a clinical-stage biotechnology company at the forefront of CRISPR/Cas9 gene-editing technology, developing potentially curative single-dose therapies for severe genetic diseases.</li>
  <li>The company's lead in vivo (in-body) candidates, lonvoguran ziclumeran (lonvo-z) for Hereditary Angioedema (HAE) and nexiguran ziclumeran (nex-z) for Transthyretin (ATTR) Amyloidosis, are in late-stage clinical trials, representing significant near-term catalysts and market opportunities.</li>
  <li>As a pre-commercial entity, Intellia is characterized by a high-risk, high-reward investment profile, with its valuation heavily dependent on clinical trial outcomes, regulatory approvals, and its ability to manage significant cash burn from intensive R&amp;D activities.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  
Intellia Therapeutics is a clinical-stage biotechnology company at the forefront of CRISPR/Cas9 gene-editing technology, developing potentially curative single-dose therapies for severe genetic diseases.
  The company's lead in vivo (in-body) candidates, lonvoguran ziclumeran (lonvo-z) for Hereditary Angioedema (HAE) and nexiguran ziclumeran (nex-z) for Transthyretin (ATTR) Amyloidosis, are in late-stage clinical trials, representing significant near-term catalysts and market opportunities.
  As a pre-commercial entity, Intellia is characterized by a high-risk, high-reward investment profile, with its valuation heavily dependent on clinical trial outcomes, regulatory approvals, and its ability to manage significant cash burn from intensive R&amp;D activities.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Intellia Therapeutics  (NTLA US) - Apr 2026

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

<ul><li>Intellia Therapeutics shares nosedived by 40% on October 27, 2025, after the company abruptly paused two critical Phase 3 clinical trials for its lead gene-editing candidate, nex-z.</li><li>The suspension follows the hospitalization of an elderly patient treated with nex-z who experienced elevated liver enzymes and bilirubin levels—early markers of liver injury.</li><li>This development casts a dark cloud over nex-z, a therapy that had been projected to drive 62% of Intellia’s estimated 2030 revenues and was central to the company’s valuation narrative.</li></ul>

Intellia Therapeutics shares nosedived by 40% on October 27, 2025, after the company abruptly paused two critical Phase 3 clinical trials for its lead gene-editing candidate, nex-z.The suspension follows the hospitalization of an elderly patient treated with nex-z who experienced elevated liver enzymes and bilirubin levels—early markers of liver injury.This development casts a dark cloud over nex-z, a therapy that had been projected to drive 62% of Intellia’s estimated 2030 revenues and was central to the company’s valuation narrative.

Intellia Therapeutics Stock Plunge: What Does The Safety Scare In Gene-Editing Trials Mean?

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<ul>
<li>We remain bullish since our 4/22/25 Compass, and we will maintain our bullish outlook as long as market dynamics remain healthy and the S&amp;P 500 (SPX) is above 6028-6059.</li>
<li>For now, we continue to expect support to show up at the 4-month uptrend, which generally coincides with the 20-day MA.</li>
<li>Speculative growth themes and metals/mining (GDX, XME) remain leadership, which we expect to continue through year-end and into the early part of 2026</li>
</ul>


We remain bullish since our 4/22/25 Compass, and we will maintain our bullish outlook as long as market dynamics remain healthy and the S&amp;P 500 (SPX) is above 6028-6059.
For now, we continue to expect support to show up at the 4-month uptrend, which generally coincides with the 20-day MA.
Speculative growth themes and metals/mining (GDX, XME) remain leadership, which we expect to continue through year-end and into the early part of 2026


S&P 500 and Russell 2000 4+ Month Uptrends Intact; Stick With Growth Themes and Metals/Mining

Research from Water Tower Research, Water Tower Research

Water Tower Research

Research from Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Equity Research Firm

Thematic (Sector/Industry)

<ul><li>The holiday-shortened week was fairly quiet on the macro front, as certain vaccine-related actions by health agencies were largely expected.</li><li>Mainly affected was MRNA, which had a new COVID-19 vaccine approved with a restrictive label and HHS funding canceled for pre-pandemic bird flu vaccines.</li><li>Public comments for the Section 232 investigation are rolling out, signaling pharma tariffs could be imminent, with expectations of ~25%.</li></ul>

The holiday-shortened week was fairly quiet on the macro front, as certain vaccine-related actions by health agencies were largely expected.Mainly affected was MRNA, which had a new COVID-19 vaccine approved with a restrictive label and HHS funding canceled for pre-pandemic bird flu vaccines.Public comments for the Section 232 investigation are rolling out, signaling pharma tariffs could be imminent, with expectations of ~25%.

Biopharma Week in Review - Possible Calm Before the Storm; Pharma Tariffs Looming

<ul><li>We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&amp;A.</li><li>The short holiday week saw another controversial name picked for NIH head, PSTX was acquired by RHHBY, AMGN underwhelmed with obesity data, and Medicare proposed to cover LLY and NVO obesity drugs.</li><li>In addition, SRPT filled its pipeline with ARWR assets, BHVN’s poor SMA results benefited SRRK, and MRK expanded its PAH drug benefit.</li></ul>

We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&amp;A.The short holiday week saw another controversial name picked for NIH head, PSTX was acquired by RHHBY, AMGN underwhelmed with obesity data, and Medicare proposed to cover LLY and NVO obesity drugs.In addition, SRPT filled its pipeline with ARWR assets, BHVN’s poor SMA results benefited SRRK, and MRK expanded its PAH drug benefit.

Biopharma Week in Review - December 2, 2024

United States

Intellia Therapeutics, Inc. operates as a biotechnology company. The Company focuses on the research and clinical development of gene editing therapies for patients with genetically-based diseases.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Intellia Therapeutics (NTLA US)

Primer: Intellia Therapeutics (NTLA US) - Apr 2026

Intellia Therapeutics is a clinical-stage biotechnology company at the forefront of CRISPR/Cas9 gene-editing technology, developing potentially...

αSK

Intellia Therapeutics Stock Plunge: What Does The Safety Scare In Gene-Editing Trials Mean?

Intellia Therapeutics shares nosedived by 40% on October 27, 2025, after the company abruptly paused two critical Phase 3 clinical trials for its...

Baptista Research

S&P 500 and Russell 2000 4+ Month Uptrends Intact; Stick With Growth Themes and Metals/Mining

S&P 500 and Russell 2000 4+ Month Uptrends Intact; Stick With Growth Themes and Metals/Mining $GDX $XME $ARKG $ARKK $ARKQ $ARKX $ARKW $ARKF $GRAL...

Vermilion Research

Biopharma Week in Review - Possible Calm Before the Storm; Pharma Tariffs Looming

The holiday-shortened week was fairly quiet on the macro front, as certain vaccine-related actions by health agencies were largely expected.

Water Tower Research

Biopharma Week in Review - December 2, 2024

The short holiday week saw another controversial name picked for NIH head, PSTX was acquired by RHHBY, AMGN underwhelmed with obesity data

Water Tower Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)